title: [Selective serotonin reuptake inhibitors (SSRI) and osteoporosis].
abstract: Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.
authors.affiliation: Service de psychiatrie générale, Département de santé mentale et de psychiatrie, HUG, 121I Genève 14. anne-catherine.will-fetique@hcuge.ch
authors.forename: Anne-Catherine
authors.initials: AC
authors.lastname: Fétique-Will
authors.forename: Thierry
authors.initials: T
authors.lastname: Chevalley
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D003863:Depression / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors